Cellectis S.A. Overview
Pro stress-test →Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company pioneers an allogeneic approach for CAR-T immunotherapies in oncology, developing off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. This represents a significant innovation versus conventional autologous approaches.
Strategic Profile
Pro stress-test →Cellectis has 25 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. The company develops a new generation of immunotherapy product candidates with additional safety and efficacy attributes equipped to resist mechanisms that inhibit immune system activity. The allogeneic CAR-T approach offers significant competitive advantages over standard autologous therapies.
Competitive Landscape
Pro stress-test →Cellectis competes in the CAR-T therapy space after pivoting from meganuclease technology to immunotherapy focus. The company faces competition from both established CAR-T players (Juno/Celgene, Kite/Gilead) and emerging allogeneic platforms. Cellectis' differentiated allogeneic approach and proprietary TALEN editing technology provide competitive advantages in manufacturing efficiency and off-the-shelf deployment.
Industry Context
Cellectis S.A. operates in Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy).
Key facts
Founded: 1999 · Headquarters: Paris, France · Employees: 216 · Revenue: N/A · Market cap: $122.11M